City of Hope and Imugene dose patient in Phase 1 trial to test cancer-killing oncolytic virus

City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours

Mental wellness startup Lissun targets phygital presence in over 25 cities this year

The centres will be located in Tier I and Tier II cities

Adroit BioMed launches Fortisil range of skincare products

Boehringer Ingelheim’s treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program

AbbVie and Cugene announce collaboration in autoimmune diseases

AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology

Antengene announces commercial availability of Xpovio in China

The drug will be available in 600 hospitals and 105 DTPs

GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia

They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights

Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor

It is developing the drug candidate to potentially treat immunological diseases

USFDA approves novel, dual-targeted treatment for type 2 diabetes

In clinical trials, treatment proved more effective than other therapies evaluated

Boehringer Ingelheim’s signal analytics technology acquired by ArisGlobal

ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment